ProAir Respiclickalbuterol

According to the FDA label: Albuterol tablets, USP are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.

84,889 adverse event reports submitted to the FDA (2004–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with ProAir Respiclick in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
ProAir Respiclick adverse event reports by reporter sex
SexReports
Female44,022
Male23,259
Unknown50

By Age Group

View age group data as a table
ProAir Respiclick adverse event reports by reporter age group
Age groupReports
0-172,981
18-343,561
35-495,469
50-6411,593
65-748,954
75+7,012

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included ProAir Respiclick. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
ProAir Respiclick adverse event reports by reported outcome
OutcomeReports
Non-Serious50,436
Other Serious24,026
Hospitalization17,322
Death3,795
Life-Threatening1,458
Disability1,202

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for ProAir Respiclick. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
ProAir Respiclick adverse event reports by year
YearReports
2004280
200591
200673
2007100
2008346
2009162
2010191
2011354
2012496
2013540
2014665
20151,285
20162,553
20172,172
20182,274
20192,973
20206,300
20218,227
20229,816
202312,804
202415,051
202514,977
2026 (partial)3,159

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with ProAir Respiclick

In FDA adverse event reports that mention ProAir Respiclick, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026